



## Immunogenicity of Botulinum Toxin

Guest Editors:

**Dr. Sara Samadzadeh**

**Prof. Dr. Harald Hefter**

Department of Neurology,  
University of Dusseldorf,  
Moorenstr 5, D-40225 Dusseldorf,  
Germany

Deadline for manuscript  
submissions:

**25 July 2024**

### Message from the Guest Editors

This Special Issue is aimed at describing the immunogenicity of botulinum neurotoxins (BoNT). BoNTs are clostridial products and form a family of highly specialized proteins that attack the mechanism of exocytosis in a variety of cells. Different components of BoNT can all induce immune responses. Therefore, the responses to BoNTs are not uniform, and a broad spectrum of responses is observed.

Antibody formation can be life-saving on the one hand, and may be a therapy-limiting factor on the other hand. Several BoNTs have been tried for clinical applications. However, today only BoNT/A is mainly used for clinical applications owing to its long-lasting effect and low antigenicity.

However, even for the development of clinically applicable preparations of botulinum neurotoxin type A (BoNT/A), attempts at purification and improvement in biological function and reduction of immunoresistance are absolutely necessary. Thus far, in all attempts, BoNT/A-treatment can still cause primary, secondary, partial or complete treatment failure. Knowledge of the course of disease before and after BoNT/A-therapy is important.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Jay Fox**

Department of Microbiology,  
University of Virginia,  
Charlottesville, VA, USA

## Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, **CAPLus / SciFinder**, **AGRIS**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Toxicology*) / CiteScore - Q1 (*Toxicology*)

## Contact Us

---

*Toxins* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/toxins](http://mdpi.com/journal/toxins)  
[toxins@mdpi.com](mailto:toxins@mdpi.com)  
[X@Toxins\\_Mdpi](https://twitter.com/Toxins_Mdpi)